Slow down on biosimilar substitution, says Australian Senate committee
This article was originally published in Scrip
Executive Summary
Industry pleas for the Australian government to reconsider its plans for biosimilar substitution may have paid off, after a parliamentary committee said that concerns over safety expressed by industry, patients and health professionals needed to be addressed before any such move went ahead.